NovoCure Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	674.41	655.35	605.22	509.34	537.84
Revenue Growth (YoY)	8.48%	8.28%	18.82%	-5.30%	-
Cost of Revenue	167.29	166.88	137.18	128.28	114.87
Gross Profit	507.13	488.47	468.04	381.06	422.97
Selling, General & Admin	461.38	417.73	428.89	390.87	306.41
Research & Development	229.1	224.54	209.65	223.06	206.09
Total Operating Expenses	690.48	642.27	638.54	613.93	512.5
Operating Income	-183.36	-153.8	-170.5	-232.87	-89.52
Interest Income	8.7	-	-	-	-
Interest Expense	0.56	-17.55	-39.33	-41.13	-7.68
Total Non-Operating Income (Expense)	9.26	-17.55	-39.33	-41.13	-7.68
Pretax Income	-175.21	-136.25	-131.16	-191.74	-81.85
Provision for Income Taxes	-2.17	-0.02	37.47	15.3	10.69
Net Income	-173.05	-136.23	-168.63	-207.04	-92.53
Net Income to Common	-173.05	-136.23	-168.63	-207.04	-92.53
Shares Outstanding (Basic)	112	111	108	106	105
Shares Outstanding (Diluted)	112	111	108	106	105
Shares Change (YoY)	3.49%	3.37%	1.36%	1.65%	-
EPS (Basic)	-1.53	-1.22	-1.56	-1.95	-0.88
EPS (Diluted)	-1.53	-1.22	-1.56	-1.95	-0.88
Shares Outstanding	115.82	112.49	108.52	107.08	105.05
Free Cash Flow	-48.07	-75.68	-69.22	-100.43	9.43
Free Cash Flow Per Share	-0.43	-0.68	-0.64	-0.94	0.09
Gross Margin	75.20%	74.54%	77.33%	74.81%	78.64%
Operating Margin	-27.19%	-23.47%	-28.17%	-45.72%	-16.64%
Profit Margin	-25.66%	-20.79%	-27.86%	-40.65%	-17.20%
FCF Margin	-7.13%	-11.55%	-11.44%	-19.72%	1.75%
EBITDA	-167.91	-139.15	-159.26	-221.9	-78.9
EBITDA Margin	-24.90%	-21.23%	-26.31%	-43.57%	-14.67%
EBIT	-183.36	-153.8	-170.5	-232.87	-89.52
EBIT Margin	-27.19%	-23.47%	-28.17%	-45.72%	-16.64%
Effective Tax Rate	1.24%	0.02%	-28.56%	-7.98%	-13.06%

Updated Apr 30, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q